secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2022-01-12T23:59:59+00:00
Accession:  0001193125-22-007689
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical prelim Q4 rev $33.1-33.4M, FY rev $94.1-94.4M (+64-65% YoY)
--------------------------------------------------------------------------

- Preliminary Q4 2021 revenue $33.1M-$33.4M (up 37-39% YoY); FY 2021 revenue $94.1M-$94.4M (up 64-65% YoY).
- Full-year revenue at high end of prior guidance range of $90M-$95M.
- Sequential Q4 revenue growth of 53-54% vs Q3 2021.
- CEO cites strength of direct sales channel, DTC, and surgeon training programs.
- Company to provide 2022 financial guidance on Q4 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000119312522007689/0001193125-22-007689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000119312522007689/d264837d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-007689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer